According to filings with the U.S. Securities and Exchange Commission, Orthogon Therapeutics is raised $11 Million in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Orthogon Therapeutics
Orthogon is a polyomavirus-focused biotech built on a proprietary discovery platform that fuses structure-based drug design with deep biophysical interrogation of viral proteins, unlocking targets long considered undruggable. The company is headquartered in Greater Boston with a research branch in Leuven, Belgium.

To learn more, visit https://orthogontherapeutics.com/
Linkedin Page: https://www.linkedin.com/company/orthogon-therapeutics/

Contact:
Ali Munawar, Chief Executive Officer
https://www.linkedin.com/in/amunawar/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.